Frontiers in Oncology (Jun 2023)
Editorial: Overcoming drug relapse and therapy resistance in NSCLC
- Sagun Parakh,
- Sagun Parakh,
- Sagun Parakh,
- Tracy L. Leong,
- Tracy L. Leong,
- Tracy L. Leong,
- Tracy L. Leong,
- Sarah A. Best,
- Sarah A. Best,
- Ashleigh R. Poh,
- Ashleigh R. Poh
Affiliations
- Sagun Parakh
- Department of Medical Oncology, Austin Health, Heidelberg, VIC, Australia
- Sagun Parakh
- Tumor Targeting Laboratory, The Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
- Sagun Parakh
- School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia
- Tracy L. Leong
- Department of Respiratory Medicine, Austin Health, Heidelberg, VIC, Australia
- Tracy L. Leong
- Faculty of Medicine, University of Melbourne, Parkville, VIC, Australia
- Tracy L. Leong
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
- Tracy L. Leong
- Department of Medical Biology, University of Melbourne, Melbourne, Australia
- Sarah A. Best
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
- Sarah A. Best
- Department of Medical Biology, University of Melbourne, Melbourne, Australia
- Ashleigh R. Poh
- School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia
- Ashleigh R. Poh
- Cancer and Inflammation Laboratory, The Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia
- DOI
- https://doi.org/10.3389/fonc.2023.1230475
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
- drug resistance
- non-small cell lung cancer
- metabolism
- tumor microenvironment
- biomarkers
- tumor mutational burden (TMB)